Filippo de Braud
University of Milan
CancerInternal medicineSurgeryPathologyOncologyAdverse effectClinical endpointLung cancerChemotherapyRenal cell carcinomaImmunotherapyRegimenIn patientCancer researchColorectal cancerBreast cancerClinical trialMedicineGastroenterologyPharmacology
621Publications
69H-index
15.2kCitations
Publications 627
Newest
#1Federico Nichetti (University of Milan)H-Index: 9
#2Francesca LigorioH-Index: 2
Last. Marco PlataniaH-Index: 14
view all 10 authors...
Hospitalized cancer patients are at increased risk for Thromboembolic Events (TEs). As untailored thromboprophylaxis is associated with hemorrhagic complications, the definition of a risk-assessment model (RAM) in this population is needed. INDICATE was a prospective observational study enrolling hospitalized cancer patients, with the primary objective of assessing the Negative Predictive Value (NPV) for TEs during hospitalization and within 45 days from discharge of low-grade Khorana Score (KS ...
Source
#1Erika Martinelli (Seconda Università degli Studi di Napoli)H-Index: 41
#2Giulia Martini (Seconda Università degli Studi di Napoli)H-Index: 14
Last. Pietro Paolo Vitiello (Seconda Università degli Studi di Napoli)H-Index: 7
view all 30 authors...
Importance null Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment with cetuximab plus avelumab with overall survival (OS) may be worthy of investigation in this setting. null Objective null To assess the efficacy and safety of cetuximab rechallenge therapy plus avelumab. n...
Source
#1Lorenza Di GuardoH-Index: 12
#2Giovanni RandonH-Index: 6
Last. Gianfrancesco GallinoH-Index: 16
view all 21 authors...
BACKGROUND Outcomes of patients with metastatic melanoma discontinuing BRAF-targeted therapy for cumulative toxicity after sustained response are unknown. MATERIALS AND METHODS This retrospective case series analysis conducted at a single Cancer Center in Italy included patients with BRAF mutated metastatic melanoma treated with a BRAF inhibitor as a single agent or in combination with a MEK inhibitor between June 1, 2011 and January 1, 2020 and interrupted treatment due to cumulative toxicity a...
Source
#2Giovanni FucàH-Index: 16
Last. Rosalba MiceliH-Index: 63
view all 11 authors...
Background:The RECOURSE trial (Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies) demonstrated an overall survival (OS) benefit of trifluridine/ti...
2 CitationsSource
#1Sara Manglaviti (University of Milan)H-Index: 3
#2Marta Brambilla (University of Milan)H-Index: 21
Last. Giuseppe Viscardi (Seconda Università degli Studi di Napoli)H-Index: 10
view all 25 authors...
Abstract null null Background null Immune-checkpoint inhibitors (ICIs) have significantly improved outcome of advanced non-small cell lung cancer (aNSCLC) patients. However, their efficacy remains uncertain in uncommon histologies (UH). null null null Materials and Methods null Data from ICI treated aNSCLC patients (April,2013-January,2021) in one Institution were retrospectively collected. Univariate and multivariate survival analyses were estimated by Kaplan-Meier and Cox proportional hazards ...
Source
#1Do-Youn Oh (Seoul National University Hospital)H-Index: 56
#2Filippo de Braud (University of Milan)H-Index: 69
Last. Lin Shen (PKU: Peking University)H-Index: 16
view all 14 authors...
Source
#1Roberto FerraraH-Index: 19
#2Elena JachettiH-Index: 14
Last. Alessandro De TomaH-Index: 11
view all 24 authors...
Background: HPD has been described in 14-26% of NSCLC pts upon single agent ICI and correlates with poor survival. Currently, HPD occurrence has not been explored upon ICI-PCT and biomarkers of HPD are lacking. Although high circulating neutrophils (Ns) correlated with HPD in NSCLC pts, the role of specific Ns subsets is unknown. null Methods: NSCLC pts treated with 1st line ICI as single agent or in combination with PCT were assessed for HPD and circulating Ns9 phenotype. Tumor response was eva...
Source
#1Koichi GotoH-Index: 55
#2Oliver GautschiH-Index: 51
Last. Pearl Plernjit French (Eli Lilly and Company)H-Index: 3
view all 12 authors...
Source
#1Martina TorchioH-Index: 8
#2Laura CattaneoH-Index: 12
Last. Giulia Bertino (UNIPV: University of Pavia)H-Index: 19
view all 15 authors...
This case report shows, for the first time, a patient experiencing a complete response after one dose of avelumab following extensive disease progression with prior electrochemotherapy (ECT) treatment. We suggest that ECT may help to establish a tumor microenvironment favorable to immunotherapy. Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with seldom durable chemotherapy responses. ECT has recently emerged as a potential treatment option for several malignancies, including MCC...
Source
#3Anna Tessari (OSU: Ohio State University)H-Index: 5
Collecting duct carcinoma (CDC) is a rare and highly aggressive kidney cancer subtype with poor prognosis and no standard treatments. To date, only a few studies have examined the transcriptomic portrait of CDC. Through integration of multiple datasets, we compared CDC to normal tissue, upper-tract urothelial carcinomas, and other renal cancers, including clear cell, papillary, and chromophobe histologies. Association between CDC gene expression signatures and in vitro drug sensitivity data was ...
1 CitationsSource